The number of patients with metastatic non-small cell lung cancer eligible for subsidised treatment with pembrolizumab is set to triple, the federal Minister for Health, Greg Hunt, has announced.

In a move expected to benefit 4000 Australians with advanced disease, he has approved two new PBS indications and loosened restrictions on an existing indication.

Here are the indications for previously untreated patients with metastatic disease:

Read more: Five-year results are in for pembrolizumab